Non-small Cell Lung Cancer Clinical Trials
Non-small Cell Lung Cancer clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for non-small Cell Lung Cancer. Corterve aggregates actively recruiting Non-small Cell Lung Cancer studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.
Recruiting Non-small Cell Lung Cancer studies
- Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLCNCT07489066PHASE2PfizerHuntsville, Alabama
- A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)NCT07513376PHASE3Merck Sharp & Dohme LLCNew Haven, Connecticut
- Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy ProtocolsNCT02682667National Cancer Institute (NCI)Bethesda, Maryland
- Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)NCT04198766PHASE1, PHASE2Inhibrx Biosciences, IncDuarte, California
- Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerNCT05267626PHASE1, PHASE2Aulos Bioscience, Inc.Miami, Florida
- AOH1996 for the Treatment of Refractory Solid TumorsNCT05227326PHASE1City of Hope Medical CenterScottsdale, Arizona
- A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)NCT06077760PHASE3Merck Sharp & Dohme LLCAnchorage, Alaska
- Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid TumorsNCT06218914PHASE1AstraZenecaDuarte, California
- A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsNCT06427941PHASE1BeOne MedicinesGoodyear, Arizona
- A Phase I Study of SIM0505 in Participants With Advanced Solid TumorsNCT06792552PHASE1NextCure, Inc.Orlando, Florida
- DK222 Study at HopkinsNCT07140315PHASE1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimore, Maryland
- Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLCNCT06745882PHASE2H. Lee Moffitt Cancer Center and Research InstituteTampa, Florida
Non-small Cell Lung Cancer trials by state
Non-small Cell Lung Cancer trials by metro
Frequently asked questions
- How do I find recruiting Non-small Cell Lung Cancer clinical trials?
- Corterve aggregates actively recruiting Non-small Cell Lung Cancer studies from the public ClinicalTrials.gov registry. Browse the studies listed on this page or take a free health assessment to see trials you may qualify for based on your profile.
- Are Non-small Cell Lung Cancer clinical trials free to join?
- Study participation is typically free — research sponsors cover the cost of the investigational treatment and study-related visits. Many trials also compensate participants for time and travel. Details vary by study.
- Who can take part in a Non-small Cell Lung Cancer clinical trial?
- Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.